These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32527038)

  • 1. Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?-Results from the ADRED Study.
    Just KS; Dormann H; Schurig M; Böhme M; Fracowiak J; Steffens M; Scholl C; Seufferlein T; Gräff I; Schwab M; Stingl JC
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32527038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalising drug safety-results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED).
    Just KS; Dormann H; Böhme M; Schurig M; Schneider KL; Steffens M; Dunow S; Plank-Kiegele B; Ettrich K; Seufferlein T; Gräff I; Igel S; Schricker S; Jaeger SU; Schwab M; Stingl JC
    Eur J Clin Pharmacol; 2020 Mar; 76(3):439-448. PubMed ID: 31832731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
    Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
    JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
    Alshabeeb MA; Alyabsi M; Paras B
    Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
    Chambal M; Forsthoffer C; Egnaczyk A; Seitz M; Grande K; Ashcraft K; Wick JA; Blaxall BC
    J Am Pharm Assoc (2003); 2023; 63(3):939-945. PubMed ID: 37024375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System-Results From the ADRED Study.
    Just KS; Dormann H; Freitag M; Schurig M; Böhme M; Steffens M; Scholl C; Seufferlein T; Graeff I; Schwab M; Stingl JC
    Front Pharmacol; 2021; 12():624104. PubMed ID: 34025403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
    Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
    Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors.
    Eugene AR
    PeerJ; 2019; 7():e7860. PubMed ID: 31616600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing.
    Vermehren C; Søgaard Nielsen R; Jørgensen S; Drastrup AM; Westergaard N
    J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32752034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
    Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
    J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States.
    Stevenson JM; Alexander GC; Palamuttam N; Mehta HB
    Clin Transl Sci; 2021 Jan; 14(1):153-162. PubMed ID: 33085221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Drug Reactions (ADR) and Emergencies.
    Schurig AM; Böhme M; Just KS; Scholl C; Dormann H; Plank-Kiegele B; Seufferlein T; Gräff I; Schwab M; Stingl JC
    Dtsch Arztebl Int; 2018 Apr; 115(15):251-258. PubMed ID: 29735005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of drugs with pharmacogenomics (PGx)-based dosing guidelines in a Danish cohort of persons with chronic kidney disease, both on dialysis and not on dialysis: Perspectives for prescribing optimization.
    Westergaard N; Baltzer Houlind M; Christrup LL; Juul-Larsen HG; Strandhave C; Olesen AE
    Basic Clin Pharmacol Toxicol; 2024 Apr; 134(4):531-542. PubMed ID: 38308569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug-Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients.
    Westergaard N; Søgaard Nielsen R; Jørgensen S; Vermehren C
    J Pers Med; 2020 Jan; 10(1):. PubMed ID: 31963319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults.
    Chan SL; Ng HY; Sung C; Chan A; Winther MD; Brunham LR; Wee HL
    Pharmacogenomics J; 2019 Aug; 19(4):401-410. PubMed ID: 30250149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
    Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study.
    Just KS; Dormann H; Schurig M; Böhme M; Steffens M; Plank-Kiegele B; Ettrich K; Seufferlein T; Gräff I; Igel S; Schricker S; Jaeger SU; Schwab M; Stingl JC
    Br J Clin Pharmacol; 2020 Nov; 86(11):2144-2154. PubMed ID: 32250457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence.
    Schuh MJ; Crosby S
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.